IL-17 inhibitors for psoriasis

The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab,ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatmentof moderate-to-severe plaque psoriasis. Clinical efficacy, safety, and tolerability of each agent is reviewed.

The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis.

Purchase this article:

PURCHASE FOR $25

For unlimited access to all issues and articles:

SUBSCRIBE NOW LOG IN TO ACCOUNT

If you do not subscribe to Seminars in Cutaneous Medicine and Surgery, you may purchase instant access for your personal use. Terms and conditions will apply (see Copyright & Terms of Use). If you need assistance, contact Susan Hite ([email protected]).